Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
G. Fragoulis, Stefan Siebert
Musculoskeletal Care (2022) Vol. 20, Iss. S1
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
Robert Bissonnette, Andreas Pinter, Laura K. Ferris, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 6, pp. 510-521
Closed Access | Times Cited: 31
Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment
Bong-Woo Lee, Su‐Jin Moon
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11662-11662
Open Access | Times Cited: 33
Interleukin inhibitors and the associated risk of candidiasis
Sabir Khan, Hazrat Bilal, Muhammad Nadeem Khan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
Fabrizio Calapai, Ilaria Ammendolia, Luigi Cardia, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1933-1933
Open Access | Times Cited: 13
JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans
Anne M. Fourie, Xiaoli Cheng, Leon Chang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
The role of mediators in the formation of leading pathological processes in psoriatic arthritis
D. A. Pogonchenkova, L. V. Chetvernya, Olga A. Vasil'yeva, et al.
Bulletin of Siberian Medicine (2025) Vol. 23, Iss. 4, pp. 187-196
Open Access
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
Sebastian Yu, An‐Ping Huo, Yu‐Hsun Wang, et al.
BioDrugs (2025)
Open Access
Pathological significance of sex hormones (testosterone and estrogen) associated with pro-inflammatory cytokines (IL-12, IL-17A, and IL-23) in patients with psoriasis and psoriatic arthritis
Randa R. Ghamyes, Abdul Kareem A. AL-Kazaz
Revista Colombiana de Reumatología (2025)
Closed Access
Verlauf der psoriatischen Erkrankung: Prävention der Psoriasis-Arthritis möglicherweise bald greifbar
Michaela Köhm, Magdalena Figat, Andreas Pinter, et al.
Deutsches Ärzteblatt (2025)
Closed Access
Psoriasis und Psoriasis-Arthritis: Unklare Datenlage zur Prävention der Gelenkbeteiligung
Michaela Köhm, Magdalena Figat, Andreas Pinter, et al.
Deutsches Ärzteblatt (2025)
Closed Access
Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness
Christian K. Kerut, Maxwell J Wagner, Charles P Daniel, et al.
Cureus (2023)
Open Access | Times Cited: 7
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study
Piero Ruscitti, Giulia Cataldi, Martina Gentile, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 3, pp. 539-551
Open Access | Times Cited: 2
Bimekizumab for the treatment of psoriatic arthritis
Yoshiya Tanaka, Stevan Shaw
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 2, pp. 155-168
Open Access | Times Cited: 6
A Snapshot of Biomarkers in Psoriasis
Krushna Abhale, Veeranjaneyulu Addepalli, Shivani Desai
Current Drug Discovery Technologies (2024) Vol. 22, Iss. 1
Closed Access | Times Cited: 2
Interleukin levels and depressive symptoms in psoriatic arthritis patients: insights from a case–control study on socio-demographic factors and disease perception
Marzena Waszczak-Jeka, Paweł Żuchowski, Marta Dura, et al.
Rheumatology International (2024) Vol. 44, Iss. 7, pp. 1337-1343
Closed Access | Times Cited: 2
Targeting cytokines in psoriatic arthritis
Laura Neurath, Michael Sticherling, Georg Schett, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 78, pp. 1-13
Open Access | Times Cited: 2
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity
Fatemeh Navid, Liye Chen, Paul Bowness, et al.
Nature Reviews Rheumatology (2024)
Closed Access | Times Cited: 2
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group
Vicenç Rocamora, Laura Crespí, Marta Ferrán, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 11
Closed Access | Times Cited: 8
Effectiveness of anti‐interleukin‐23 therapy in psoriatic arthritis: A pilot prospective real‐world study
Tümay Ak, Sera Nur Yücesoy, Meliksah Taner, et al.
International Journal of Rheumatic Diseases (2023) Vol. 26, Iss. 5, pp. 878-884
Closed Access | Times Cited: 4
Pharmacotherapeutic management of psoriatic disease: addressing psoriatic Arthritis and cutaneous manifestations
Robin C. Yi, Hannah Y. Gantz, Shimul A. Shah, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 16, pp. 2203-2212
Closed Access | Times Cited: 1
Interleukin-17–targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile
Rubén Queiró, Elena Aurrecoechea, Sara Alonso-Castro, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
Michaela Koehm, Frank Behrens
RMD Open (2023) Vol. 9, Iss. 3, pp. e003166-e003166
Open Access | Times Cited: 2
The Effects of IL-23/IL-18-Polarized Neutrophils on Renal Ischemia–Reperfusion Injury and Allogeneic-Skin-Graft Rejection in Mice
Changhong Wu, Jinglin Xu, Zhaoqi Zhang, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3148-3148
Open Access | Times Cited: 1
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Laura C. Coates, Proton Rahman, Philip J. Mease, et al.
BMC Rheumatology (2024) Vol. 8, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top